Valeant pays down $811M in senior secured loans after Dendreon Pharma sale

Valeant Pharmaceuticals used $811 million of the $819.9 million it received for selling Dendreon Pharmaceuticals to pay down some of the company's senior secured loans.

Here's what you should know:

1. Valeant has paid all mandatory amortizations through 2019.

2. Since the first quarter of fiscal year 2016, Valeant reduced its debt by more than $4.3 billion.

3. Valeant executives believe the company will pay approximately $5 billion in debt by February 2018.

4. Valeant sold Dendreon Pharmaceuticals to Sanpower Group on June 29. .

More articles on gastroenterology:
The 20 states with the best and worst colorectal cancer screening rates
Takeda CEO facing pressure amid dismal profits — 4 key notes
Allergan sues Sun Pharma for patent infringement — 3 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months